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A B S T R A C T
Bone repair is a multi-dimensional process that requires osteogenic cells, an osteoconductive matrix,
osteoinductive signalling, mechanical stability and vascularization. In clinical practice, bone substitute
materials are being used for reconstructive purposes, bone stock augmentation, and bone repair. Over
the last decade, the use of calcium phosphate (CaP) based bone substitute materials has increased
exponentially. These bone substitute materials vary in composition, mechanical strength and biological
mechanism of function, each having their own advantages and disadvantages. It is known that intrinsic
material properties of CaP bone substitutes have a profound effect on their mechanical and biological
behaviour and associated biodegradation. These material properties of bone substitutes, such as
porosity, composition and geometry change the trade-off between mechanical and biological
performance. The choice of the optimal bone substitutes is therefore not always an easy one, and
largely depends on the clinical application and its associated biological and mechanical needs. Not all
bone graft substitutes will perform the same way, and their performance in one clinical site may not
necessarily predict their performance in another site. CaP bone substitutes unfortunately have yet to
achieve optimal mechanical and biological performance and to date each material has its own trade-off
between mechanical and biological performance. This review describes the effect of intrinsic material
properties on biological performance, mechanical strength and biodegradability of CaP bone substitutes.
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Annually, more than 2.2 million bone grafting procedures are
performed worldwide.1 The current gold standard for bone repair
is the use of autologous bone grafts harvested from a remote site in
the patient. A few of the many problems associated with autografts
include donor site morbidity and the restricted availability.2 In
addition to autografts, success has been reported with the use of
allografts. Like the autografts, these allografts are also limited in
supply and there exists a risk of disease transmission and immune
rejection. Despite the beneﬁts of both autografts and allografts, the
relative concerns over their use has led to the development of
numerous synthetic bone substitutes.
One of the most promising groups of synthetic bone substitutes
are calcium phosphate ceramics (CaPs). The most commonly used
CaPs are hydroxyapatite (HA) and tricalcium phosphate (TCP) or an
intrinsic combination of the two.3,4
The rationale for the development of CaPs has been their
similarity in composition to bone mineral and their similarities in* Corresponding author. Tel.: +31 43 3874502.
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osteoconductivity. Another important property of bone, inter-
connecting porosity can be introduced during the manufacturing
process of CaPs. Besides these desirable properties, CaPs are known
to have relatively low mechanical properties and are therefore
mostly not suitable for application in load-bearing areas, as they do
not provide sufﬁcient structural support.5 A proper understanding
of these properties, both biological and mechanical, are critical for
the successful application of CaPs as bone substitutes. In this
review we describe and discuss the interaction between these
properties in search of what is optimal for bone regeneration.
Bone cell–ceramic interactions
Although TCP and HA derived through thermal treatment do
not exist naturally, they have been shown to induce a biological
response similar to that of bone.3,5 Cells attach to and engulf the
CaPs, causing them to biodegrade in vitro and in vivo. CaPs allow
osteoblast cells to attach, proliferate, and differentiate. Differenti-
ating osteoblast cells produce collagen type I, alkaline phospha-
tase, proteoglycans, and matrix proteins, such as osteocalcin,
osteopontin, and bone sialoprotein known to signify bone
formation.5 Cellular response is affected by the composition of
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or ﬂuoride (F) from F-apatite or carbonate-F-apatite have been
shown to inhibit osteoclastic activity.5,6 On the other hand, F in F-
apatite or Mg or Zn and/or F or combination of the three ions in
carbonate apatite matrix was shown in vitro to promote collagen
production and phenotypic expression of proteoglycans and
matrix proteins associated with bone mineralization. The forma-
tion of distinct resorption pits on HA and TCP surfaces in the
presence of osteoclasts was also observed.7,8 Factors that affect
cellular response to CaPs include surface topography (roughness),
geometry, composition, and particle size.5
Biodegradability
Ideally, the rate of resorption of CaPs is similar to the rate of new
bone formation but for obvious reasons not any faster. In vivo
biodegradability can be achieved by dissolution or is cell mediated.
The population of cells responsible for the resorption of CaPs
mainly consists of multinuclear cells and osteoclasts.7,8 However,
macrophages are involved in the phagocytosis of CaPs as well.9 The
speed of biodegradability and the cell type involved in the
resorption process are determined by both material properties,
such as Ca/P ratio, crystallinity, particle size, surface area, and
porosity and the local biological environment, such as pH, the
presence of cells, and H2O content.
3 In general, CaPs consisting of
TCP have higher degradation rates as compared to CaPs consisting
of HA.10
Recently, new tools have been developed to assess the
incorporation, remodelling, and resorption of biomaterials in
patients. High-resolution peripheral QCT makes it possible to
assess changes in bone and biomaterial/CaP structure and density
in vivo/in situ with a relatively high (82 mm) resolution.11 The low
radiation exposure associated with this technique makes longitu-
dinal follow-up in patients possible and will provide long-term
clinical data of the incorporation, remodelling and resorption bone
substitute materials over time. In addition, FEA models can be
build from the QCT images to quantify changes in bone and bone
graft substitute strength. Another, promising method to follow
bone metabolism and blood ﬂow in patients is 18F-ﬂuoride PET
scanning.12,13 However, data on the long-term follow-up of CaP
bone substitutes implanted in patients is still rather limited.
Pore size
Pores in calcium phosphate materials are necessary for bone
tissue formation because they allow migration and proliferation of
osteoblasts and mesenchymal cells, as well as vascularization. In
addition, a porous surface improves mechanical interlocking
(interdigitation) between the implant biomaterial and the
surrounding natural bone, providing greater mechanical stability
at this critical interface.14
Pore size can be divided in two different groups: microporous
(<5 mm pores) and macroporous (>100 mm pores).14,15 Micropo-
rosity and macroporosity are important for the bioresorbability of
the material. In addition, macroporosity plays an important role in
the osteoconductivity.3,5
The minimum recommended pore size for a bone substitute is
100 mm,16 but subsequent studies have shown better osteogenesis
for substitutes with pores >300 mm.14,17,18 Smaller pores (75–
100 mm) resulted in ingrowth of unmineralized osteoid tissue or
were penetrated only by ﬁbrous tissue (10–44 and 44–75 mm).16
However, using laser perforation techniques and titanium plates,
four different pore sizes (50, 75, 100 and 125 mm) were tested in
rabbit femoral defects under non-load-bearing conditions.19 Bone
ingrowth was similar in all the pore sizes suggesting that 100 mm
may not be the critical pore size for non-load-bearing conditions. Avery interesting aspect of the effect of pore size on bone
regeneration is the impact on the progression towards osteogene-
sis. Relatively larger pores favour direct osteogenesis, since they
allow vascularization and high oxygenation, whilst smaller pores
result in osteochondral ossiﬁcation, although the type of bone
ingrowth depends on the material itself and the geometry of the
pores.18,20
Porosity
Many studies have demonstrated a greater degree and faster
rate of bone ingrowth or apposition with percentage porosity;
however, there still seems to be some dispute regarding the
optimum ‘‘type’’ of porosity. The rate and quality of bone
integration have been related to a dependence on pore size,
porosity volume fraction, and interconnectivity, both as a function
of structural permeability and mechanics.21 Bone regeneration in a
scaffold in vivo involves recruitment and penetration of cells from
the surrounding bone tissue, as well as vascularization. Higher
porosity is expected to enhance osteogenesis and numerous
studies have veriﬁed this hypothesis. These results were likely due
to the larger surface area that resulted in higher ion exchange and
bone-inducing factor adsorption.10,21 There are a limited number
of reports in the literature that show no effect of porosity on the
amount of apposited bone.22,23 The absence of any reports on the
beneﬁcial effects of lower porosity scaffolds in vivo solidiﬁes the
requirement of highly porous implants for bone regeneration.
Microporosity results in larger surface area that is believed to
contribute to higher bone inducing protein adsorption as well as to
ion exchange and bone-like apatite formation by dissolution and
reprecipitation.21 Surface roughness enhances attachment, prolif-
eration and differentiation of anchorage dependent bone forming
cells.5
High porosity and large pores enhance bone ingrowth and
osseointegration of the implant after surgery.14 Although there are
a few reports in literature showing no difference in the osteogenic
outcome for scaffolds with different porosities, there are no reports
indicating a beneﬁcial effect for implants with low porosity. Other
factors, such as the rate of degradation and the mechanical
performance of the scaffold should be taken into account when
porosity is assessed.
Interconnectivity
Another important factor that determines the effectiveness of
porosity is the structure of the pores with respect to each other.
The pores may either be interconnecting or they contain ‘‘dead-
ends’’.15 Interconnecting macroporosity is introduced by adding
porogens, such as naphthalene, H2O2, polymeric porogens or using
the foaming method.4 Microporosity depends on sintering
temperature or sintering program. CaP sintered at 1200 8C shows
signiﬁcantly less microporosity than that sintered at 1000 8C and a
dramatic change in crystal size.5
In general, calcium phosphates with interconnective pores are
advantageous over biomaterials containing dead-end pores, because
a spatial continuous connection of the pore system has a decisive
meaning for the ingrowth of new bone, especially in long-term tissue
interface maintenance.15 However, when used in combination with
osteogenic cells, materials containing interconnective pores are less
able to contain osteogenic cells, resulting in a longer period until the
pore space has been ﬁlled with newly formed bone.24
Biomechanical properties
The property that is most often used to characterize the
mechanical behaviour of bone substitutes is their compressive
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substitutes, it is important to keep in mind that the compressive
strength of human cortical bone ranges between 90 and 230 MPa
(with tensile strengths ranging from 90 to 190 MPa), whereas the
compressive strength of cancellous bone ranges between 2 and
45 MPa.25,26
Calcium phosphates generally provide limited biomechanical
support, because they are brittle and have little tensile strength.
TCPs are less brittle compared with HA. However, the faster
degradation of TCP results in subsequent quicker loss of
mechanical strength over time.
Although increased porosity and pore size facilitate bone
ingrowth, the result is a reduction in mechanical properties, since
this compromises the structural integrity of the scaffold. Moreover,
scaffolds fabricated from ceramics with a high degradation rate
should not have high porosities (>90%), since rapid depletion of the
material will compromise the mechanical and structural integrity
before substitution by newly formed bone.14
However, there is an upper limit in porosity and pore size set by
constraints associated with mechanical properties. An increase in
the void volume results in a reduction in mechanical strength of
the scaffold, which can be critical for regeneration in load-bearing
bones. For example, an increase of the total porous volume from 10
to 20% results in a factor four decrease in mechanical strength.15,27
The extent to which pore size can be increased whilst
maintaining mechanical requirements is dependent on many
factors, including the nature of the material and the processing
conditions used in its fabrication.
Bioactivity, osteoconductivity and osteoinductivity
Bioactivity is deﬁned as the property of materials to develop a
direct, adherent, and strong bonding with the bone tissue.3 From a
cellular perspective, bioactivity reﬂects the attachment and
differentiation of osteogenic cells on ceramic surfaces.24
Osteoconductivity is the ability of a material to serve as a
scaffold to guide formation of newly forming bone along their
surfaces. Osteoinductivity is the inherent ability of a material to
induce bone formation without the presence of osteogenic factors
and is usually demonstrated by bone formation after implantation
of these materials in an ectopic site.28,29
CaP materials are generally known to be osteoconductive but
not osteoinductive. However, several CaP materials, such as porous
synthetic and coralline HA, b-TCP, and calcium phosphate
cements, have been shown to have to ability to form bone in
ectopic sites in different animals without the addition of
osteogenic factors. The osteoinductive properties of these materi-
als appear to be based on their architectural features, such as
surface geometry, topography, pore size, and porosity which allow
entrapment and concentration of circulating BMPs in the biologic
ﬂuid.3,5,30,31 The main challenge remains to determine the
appropriate architecture for these materials to optimize the ability
to entrap and concentrate growth factors and/or osteoprogenitor
cells.
Independent of architectural features, CaPs or CaP-based
composite materials combined with BMPs, osteoprogenitor cells,
and bioactive proteins or peptides have been shown to enhance
bone formation.32–34 The main challenges for this so-called
engineered osteoinductivity are to determine the optimal scaffold,
the appropriate dose of osteogenic factors, and the controlled
release of these factors for different applications.
Discussion
The idea of an optimal bone graft substitute usable in all clinical
indications, although alluring, is an idle one. Most bone graftsubstitutes need to be inserted into a stable host site that contains
adequate vascularity and an adequate source of osteoblast
precursor cells. In an appropriate site, these graft materials are
eventually resorbed and replaced by host bone. However, if the
operative site is mechanically unstable or if there are inadequate
cells or other host factors limiting bone healing, problems may
occur. Co-morbidities of the patient, such as osteoporosis and/or
diabetes, will also negatively inﬂuence the in vivo performance and
capacity of the biomaterial to incorporate.
Therefore, the bone substitute of choice depends largely on the
clinical application and its associated biological and mechanical
needs.35 It is sensible to assume that not all bone graft substitutes
will perform the same way and that the validation of a bone graft
substitute in one clinical site may not necessarily predict its
performance in another location.1,36 Non-invasive and non-
destructive quantitative imaging modalities have become a useful
tools in monitoring the performance of CaPs in different
locations.11–13
The large variety of bone substitutes available on the market
represents not only the different clinical needs and scenarios
encountered, but also the diversity of the expected clinical
outcomes. The surgeon has to assess the requirements of the
bone defect to be grafted, think of the properties needed for repair,
and ultimately choose the appropriate bone substitute and its
associated surgical technique. The choice of the appropriate bone
substitute scaffold should be based on several parameters having
in mind that the gold standard remains the autograft.
Over the recent years, hybrid bone substitute materials have
appeared on the market. Usually the basis is an osteoconductive
TCP or HA calcium phosphate scaffold which has been combined
with other compounds to enhance the mechanical or the biological
performance.37,38 Clinical studies involving the addition of growth
factors, such as BMP-2 and BMP-7 to CaPs have demonstrated
remarkable osteoinductive capacities.39,40 The incorporation
of such factors to create osteoinductive scaffolds remains a
promising option. In the near future, complex combination
products that include cells, growth factors, and/or gene therapy
in combination with scaffolds with optimal geometries are likely to
give surgeons more effective tools for defect/application speciﬁc
bone repair.
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